Rxsight (RXST) Trading Snapshot
- Closing Price (23 Oct 2026): USD 5.03
- Daily Change: Up 0.41 % during the 24‑hour period ending 07:53 PM Central Europe.
- Market Capitalisation: USD 203.8 million.
- Shares Outstanding: 41.6 million.
- Volume (last 24 hrs): USD 2.8 million.
- Price Trend (last month): Down 0.61 %.
- 200‑Day Simple Moving Average: USD 6.53.
- 52‑Week High: USD 13.22 (12 Nov 2025).
- 52‑Week Low: USD 4.40 (14 Oct 2026).
Company Overview
RxSight, Inc. is a commercial‑stage medical technology company headquartered in Aliso Viejo, United States. The firm develops adjustable intraocular lenses (IOLs) that aid clinicians in restoring vision following cataract surgery. RxSight operates primarily in the United States and its stock is listed on the Nasdaq exchange.
Recent Market Activity
| Stock | % Move | Current Price (USD) | Market Capitalisation (USD mn) |
|---|---|---|---|
| Greenwich Lifesciences (GLSI) | +2.03 % | 15.55 | 243.2 |
| Amtech (ASYS) | –11.16 % | 12.34 | 243.2 |
| Perma‑pipe Hol (PPIH) | –3.94 % | 28.63 | 243.2 |
| Palisade Bio (PALI) | –3.57 % | 1.36 | 244.0 |
| Vanda (VNDA) | +1.00 % | 3.95 | 242.5 |
Notable Developments
Amtech (ASYS): Analyst coverage renewed by Lake Street Capital, buy rating with upside potential. The company reported earnings above consensus and experienced increased insider and institutional holdings.
Perma‑pipe Hol (PPIH): Announced a new Ohio plant lease to supply liquid‑cooling infrastructure for AI data‑center projects. The company’s fiscal 2025 net sales aligned with continued expansion in the data‑center piping market.
Palisade Bio (PALI): Filed ownership changes under Forms 3 and 4, involving acquisition of 787,300 shares by Capers Julien E. No material change in strategic direction was indicated.
Vanda (VNDA): Scheduled to release third‑quarter 2026 financial results after the market close on 28 Oct 2026. A conference call with management will be webcast and archived.
Saluda Medical Inc. Highlights
Saluda Medical Inc., a publicly listed company following its Australian Securities Exchange IPO in November 2025, reported strong performance in FY 2026. Key points include:
- Revenue Growth: Surpassed guidance and improved gross margins.
- Operating Cash Flow: Positive, indicating healthy cash generation.
- Product Expansion: U.S. FDA approval of the CAP24 paddle lead broadened the product portfolio into surgical paddle‑lead procedures.
- Strategic Focus: Continued investment in commercial infrastructure, physician education, and product development to expand market share and operating leverage.
These developments position Saluda Medical for further growth in both U.S. and international markets.
